Can AI Make Better Drugs? Not on Wall Street’s Timeline

According to a report by The Wall Street Journal, artificial intelligence (AI) is delivering a tangible leap in efficiency in drug discovery labs, predicting how proteins fold, identifying potential drug targets, and screening millions of molecules virtually. However, Wall Street is still waiting for evidence that this technology will change the economics of drug making.

Details

Traditionally, scientists have selected drug targets largely by hand, drawing on the body of research they know best to decide which proteins might matter in a disease, then spending months or years testing those hypotheses in the lab. AI can now accelerate this process significantly.

Context

The gap between technical potential and financial expectations is clear. While researchers see real progress, investors want to see tangible returns on investment. Companies like Eli Lilly (ticker: LLY) are investing heavily in this area, but the market is waiting for evidence that AI-discovered drugs will reach the market and generate revenue.

What It Means for Investors

Investors should monitor the progress of clinical trials for AI-discovered drugs and compare development costs to traditional methods. Long-term success depends on AI's ability to reduce clinical trial failure rates and accelerate time to market.